SCHEMBL2835296

SCHEMBL2835296

COc1cc(C)c(S(=O)(=O)N2CCC[C@H]2COc2ccnc(N3CCC(CCN4CCCC4)CC3)n2)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 6/20 0.40
TMEM97 Q5BJF2 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
CASP3 P42574 8/20 0.35
CASP7 P55210 6/20 0.35
HTR1A P08908 2/20 0.35
DRD2 P14416 2/20 0.35
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35
DRD3 P35462 1/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
CHRM4 P08173 1/20 0.34
CCR4 P51679 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
HTR2A P28223 1/20 0.33
HTR6 P50406 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834109 0.99 HTR7 (0.40) HTR7TMEM97SIGMAR1CASP3CASP7
SCHEMBL2839870 0.98 HTR7 (0.38) HTR7TMEM97SIGMAR1CASP3CASP7
SCHEMBL2836552 0.98 HTR7 (0.38) HTR7TMEM97SIGMAR1CASP3CASP7
SCHEMBL2832782 0.89 CA12 (0.39) HTR7TMEM97SIGMAR1CASP3CASP7
SCHEMBL2836548 0.88 CA12 (0.38) HTR7TMEM97SIGMAR1CASP3CASP7
SCHEMBL2832996 0.88 KMT2A (0.40) HTR7TMEM97SIGMAR1CASP3CASP7
SCHEMBL2836786 0.87 KMT2A (0.39) CASP3CASP7ALDH1A1KDM4ENPC1
SCHEMBL2834791 0.87 BDKRB1 (0.41) HTR7TMEM97SIGMAR1CASP3CASP7
SCHEMBL2837335 0.86 BDKRB1 (0.41) HTR7CASP3CASP7HTR1ADRD2
SCHEMBL2834666 0.86 BDKRB1 (0.40) CASP3CASP7HTR1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS HTR7 643/4885TMEM97 3649/4885SIGMAR1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.